Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Releases First Corporate Responsibility Report; Highlights Access To Medicines, Environmental Impact And Compliance

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Melbourne-headquartered CSL March 29 released its first Corporate Responsibility Report, combining information about the company's economic, social and environmental performance for 2009

You may also be interested in...



Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO

PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age

Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit

Caving in to opposition from the Federal Trade Commission, CSL Limited has scuttled its $3.1 billion deal to acquire Talecris Biotherapeutics, saying it was not worth the money and time to battle the agency in court

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC074440

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel